Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagn...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.722507/full |
| _version_ | 1818394797924155392 |
|---|---|
| author | Panagiotis T. Diamantopoulos Nora-Athina Viniou |
| author_facet | Panagiotis T. Diamantopoulos Nora-Athina Viniou |
| author_sort | Panagiotis T. Diamantopoulos |
| collection | DOAJ |
| description | Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article. |
| first_indexed | 2024-12-14T06:06:55Z |
| format | Article |
| id | doaj.art-738dd1804ff64cda93ea9196008307a2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T06:06:55Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-738dd1804ff64cda93ea9196008307a22022-12-21T23:14:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-11-011110.3389/fonc.2021.722507722507Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment ApproachesPanagiotis T. DiamantopoulosNora-Athina ViniouAtypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article.https://www.frontiersin.org/articles/10.3389/fonc.2021.722507/fullatypical chronic myelogenous leukemiamyelodysplastic syndrome/myeloproliferative neoplasmdiagnostic criteriatreatmentmolecular characterization |
| spellingShingle | Panagiotis T. Diamantopoulos Nora-Athina Viniou Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches Frontiers in Oncology atypical chronic myelogenous leukemia myelodysplastic syndrome/myeloproliferative neoplasm diagnostic criteria treatment molecular characterization |
| title | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
| title_full | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
| title_fullStr | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
| title_full_unstemmed | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
| title_short | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
| title_sort | atypical chronic myelogenous leukemia bcr abl1 negative diagnostic criteria and treatment approaches |
| topic | atypical chronic myelogenous leukemia myelodysplastic syndrome/myeloproliferative neoplasm diagnostic criteria treatment molecular characterization |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.722507/full |
| work_keys_str_mv | AT panagiotistdiamantopoulos atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches AT noraathinaviniou atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches |